Primary Sclerosing Cholangitis Key Players : Acorda Therapeutics Inc, Conatus Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Gilead Sciences Inc, NGM Biopharmaceuticals Inc, Noxopharm Ltd, and Sirnaomics Inc Market Analysis and Forecast 2018-2022
Primary Sclerosing cholangitis (PSC)
Primary Sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Bile ducts are refer to as tubes which carry bile into the upper part of the bowel. The bile also enables the body to absorb vitamins A, D, E and K from our diet.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811462-primary-sclerosing-cholangitis-pipeline-review-h1-2018
Primary Sclerosing Cholangitis Industry Major Highlights:
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Primary Sclerosing Cholangitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Apart from this various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Major Outlook for Primary Sclerosing Cholangitis Report:
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis
The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis.
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
Competitive Analysis for Primary Sclerosing Cholangitis
Key players are making innovative developments in Primary Sclerosing Cholangitis industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.
The key players in this market are Albireo Pharma Inc, Arena Pharmaceuticals Inc, Cadila Healthcare Ltd, Dr. Falk Pharma GmbH, Gilead Sciences Inc, Novartis AG, Tiziana Life Sciences Plc and Virobay Inc
Table of Contents
Global Markets Direct Report Coverage 5
Primary Sclerosing Cholangitis - Overview 6
Primary Sclerosing Cholangitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Primary Sclerosing Cholangitis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development 19
ActiveSite Pharmaceuticals Inc 19
Coherus BioSciences Inc 19
Lupin Ltd 20
Mabion SA 20
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811462-primary-sclerosing-cholangitis-pipeline-review-h1-2018
Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Key Players : Acorda Therapeutics Inc, Conatus Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Gilead Sciences Inc, NGM Biopharmaceuticals Inc, Noxopharm Ltd, and Sirnaomics Inc Market Analysis and Forecast 2018-2022 here
News-ID: 932749 • Views: 367
More Releases from WISE GUY RESEARCH CONSULTANTS PVT. LTD.
CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, T …
Summary: A new market study, titled “Discover Global CBD Snack Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Introduction “CBD Snack Market” COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm A …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017” Chronic lymphocytic leukemia (CLL) Overview Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections
Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeu …
WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report “Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018” Onychomycosis (Tinea Unguium) Overview Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Bet …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018” Non Alcoholic Fatty Liver Disease (NAFLD) Overview Non Alcoholic Fatty Liver Disease (NAFLD) this situation arise when individual have too much fats there your liver. There should be little or no fat in a healthy liver and for most people, carrying a small amount of
More Releases for Primary
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Conference on Primary Healthcare and Medicare
Healthcare conferences 2021 Paris, France organized by Pencis group. Pencis takes the privilege to invite speakers, participants, students, delegates, and exhibitors from across the globe to its Global Conference on Primary healthcare conferences 2021 and Medicare to be held in the beautiful city of Paris, France. Primary healthcare conferences 2021 is a discussion of common healthcare-related issues and additionally trade information, share proof, thoughts, and insight into advanced developments
RM Medical Search Places Primary Care Physician
RM Medical Search is pleased to announce the placement of a primary care physician with OnPoint Medical Group. OnPoint Medical Group is a Denver-based medical organization proudly led by physicians and supported by a team of proven business professionals. OnPoint Medical Group’s partnership with RM Medical Search, to find top quality physicians, furthers the organization's commitment “to make OnPoint Medical Group the preferred partner and advocate for providers and patients
Primary Hyperoxaluria - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Primary Hyperoxaluria - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2017, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape. Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Primary Functions Marketing Resource Management Market Globally
MRM software is a software that helps in managing marketing operations effectively based on MRM processes. The primary functions of MRM are marketing planning and budgeting, asset management, project management, and content management. These systems also help connect an organization's marketing departments. Organizations use MRM systems to understand the buying criteria of consumers and to market accordingly. The benefits of MRM software are shown in the following exhibit. View Sample Copy